Related Experiment Video
Updated: Aug 18, 2026

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
Assessing the impact of coverage gaps in the Medicare Part D drug benefit
Bruce Stuart1, Linda Simoni-Wastila, Danielle Chauncey
1Peter Lamy Center on Drug Therapy and Aging, Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, USA. bstuart@rx.umaryland.edu
Abstract:
The new Medicare Part D drug benefit contains major coverage gaps for people who spend moderate to high amounts on prescription drugs who qualify only for the standard coverage. To help policymakers understand the impact such gaps will have on those affected, we studied a representative sample of Medicare beneficiaries with naturally occurring prescription benefit gaps between 1998 and 2000 using data from the Medicare Current Beneficiary Survey. Our findings suggest that discontinuities in drug benefits result in sizable reductions in medication use and spending, which is magnified in people with common chronic illnesses.
Related Concept Videos
Dosage Regimens: Partial Pharmacokinetic Parameters
Drug Dosing: Geriatric Patients
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Therapeutic Drug Monitoring: Affecting Factors